Methods for controlling binge eating disorders
View Patent ↗Compositions and methods for preventing, treating or controlling conditions or disorders associated with obesity, diet, and nutrition are provided. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to prevent, treat or controlling conditions or disorders associated with obesity, diet, and nutrition.
1. A method of controlling binge eating in a human in need thereof comprising administering an effective amount of pramlintide to the human to control binge eating.
2. The method of claim 1 , wherein the effective amount is 25 μg to 240 μg.
3. The method of claim 1 , wherein pramlintide is in the form of a salt.
4. A method of controlling binge eating in a subject in need thereof comprising administering an effective amount of an amylin agonist to the subject to control binge eating.
5. The method of claim 4 , wherein the amylin agonist is administered to the subject in an amount effective to reduce the subject's Binge Eating Scale total score as compared to the Binge Eating Scale total score in the absence of administration of the amylin agonist.
6. The method of claim 4 , wherein the amylin agonist is administered to the subject in an amount effective to alter the subject's Binge Eating Scale category as compared to the Binge Eating Scale category in the absence of administration of the amylin agonist; wherein the Binge Eating Scale category is altered from severe to moderate, from severe to mild, or from moderate to mild.
7. The method of claim 4 , wherein the amylin agonist is administered at one or more times of the day when the subject is most likely to binge eat.
8. The method of claim 4 , wherein the subject binge eats when emotionally distressed.
9. The method of claim 4 , wherein the subject has an anxiety disorder.
10. The method of claim 4 , wherein the amylin agonist is a peptide comprising the amino acid sequence of any one of SEQ ID NOs:4-31.
11. The method of claim 4 , where the amylin agonist is pramlintide.
12. The method of claim 4 , wherein the effective amount is 25 μg to 240 μg.
13. The method of claim 4 , wherein the amylin agonist is in the form of a salt.
14. The method of claim 4 , wherein the subject is human.
15. The method of claim 4 , further comprising administering an effect amount of a PYY, a PYY agonist, a GLP-1, a GLP-1 agonist, a DPPIV inhibitor, a CCK, a CCK agonist, an exendin, an exendin agonist, a GIP, a GIP agonist, leptin, or a leptin agonist.
16. A method of controlling binge eating in a human in need thereof comprising administering an effective amount of a peptide comprising the amino acid sequence of SEQ ID NO:3 to the human to control binge eating.
17. The method of claim 16 , wherein the peptide comprises the amino acid sequence of any one of SEQ ID NOs:4-31.
18. The method of claim 16 wherein the peptide comprises the amino acid sequence of any one of SEQ ID NOs:4-9.
19. The method of claim 16 , wherein the peptide comprises the amino acid sequence of SEQ ID NO:6.
20. The method of claim 16 , wherein the peptide is in the form of a salt.